The activity of E2F transcription factors plays a crucial role in mammalian cell-cycle progression and is controlled by physical association with the pocket proteins (pRb and its related p107 and p130). The E2F1 promoter, which contains two overlapping E2F-binding sites, is activated at the G1/S transition in an E2F-dependent manner. Mutational experiments have shown that the distal E2F-binding site on the E2F1 promoter is required for transcriptional repression in the G0 phase, whereas the proximal E2F-binding site contributes to transcriptional activation at the G1/S boundary. Consistent with these results, chromatin immunoprecipitation assays have revealed that the E2F4/p130 repressor complex specifically binds to the distal E2F-binding site, whereas E2F1 and E2F3 activators preferentially bind to the proximal E2F-binding site. The assays also showed that the specific binding of E2F4/p130 complex to the distal site was dramatically impaired by a mutation introduced into the contiguous repression site (cell Cycle gene Homology Region; CHR). Taken together, these findings indicate that the two E2F-binding sites play distinct roles in the regulation of E2F1 transcription by interacting with different sets of E2F members and cooperating with the contiguous repressor element.
Introduction
The E2F family of transcriptional factors plays a crucial role in the mammalian cell cycle by controlling the expression of genes that mediate cell-cycle progression (e. g., cyclin E (Ohtani et al., 1995; Botz et al., 1996) and cdc2 (Dalton, 1992; Tommasi and Pfeifer, 1995) ) and DNA synthesis (e.g., DNA polymerase a (Pearson et al., 1991) and thymidine kinase (TK) (Dou et al., 1992) ). The six members of the E2F family (E2F1-6) that have been identified thus far bind to DNA by heterodimerizing with DP family members, DP1 and DP2, and the activity of E2F1-5 is regulated by physical interactions with the pocket proteins (pRb and the pRb-related proteins p107 and p130). The E2F members can be divided into three distinct subgroups based on their function and ability to bind pocket proteins. The members of the first subgroup, E2F1, E2F2 and E2F3, are potent transcriptional activators and bind almost exclusively to pRb, whereas the members of the second subgroup, E2F4 and E2F5, contribute to 'active repression' of E2F-responsive genes and bind preferentially to p107 and p130 (Dyson, 1998; Harbour and Dean, 2000; Trimarchi and Lees, 2002) . E2F6, the sole member of the third subgroup, acts as a transcriptional repressor in a pocket protein-independent manner, because it lacks the pocket protein-binding domain. The precise characteristics of E2F6, however, remain unclear (Cartwright et al., 1998; Gaubatz et al., 1998; Ogawa et al., 2002) .
There are a number of findings demonstrating the diverse transcriptional regulation of E2F-responsive genes. First, the expression patterns of E2F-responsive genes during the cell cycle are not simple. The promoter activities of E2F1 and B-myb are upregulated at the G1/S boundary (Lam and Watson, 1993; Hsiao et al., 1994; Johnson et al., 1994; Neuman et al., 1994) , whereas those of cyclin A and cdc2 are upregulated in the late S-G2 phase (Dalton, 1992; Schulze et al., 1995; Tommasi and Pfeifer, 1995; Liu et al., 1998) and that of Rb is almost unchanged throughout the cell cycle (Shan et al., 1994) . Second, mutational studies have shown that mutations introduced into E2F-binding sites in the B-myb and cdc6 promoters cause derepression in G0 (Lam and Watson, 1993; Bennett et al., 1996; Hateboer et al., 1998; Ohtani et al., 1998) , whereas those in the dihydrofolate reductase (DHFR) and TK promoters result in the absence of transactivation during cell-cycle progression (Lin et al., 1996; Karlseder et al., 1996; Rotheneder et al., 1999) . Third, studies using mouse embryonic fibroblast (MEFs) deficient in pRb or p107/ p130 have demonstrated that the transcriptional activities of the B-myb, cdc2, E2F1, and cyclin A2 promoters are derepressed in MEFs lacking p107/p130, but not in pRb-deficient MEFs. On the other hand, derepression of the cyclin E and p107 promoters occurs in MEFs lacking pRb alone, suggesting that the expression of these E2F-responsive genes is regulated by different sets of E2F-pocket protein complexes (Hurford et al., 1997) .
It is currently uncertain how individual E2F members recognize a particular E2F-binding site in each stage of the cell cycle. One possibility is that the DNA binding specificity of E2F members is influenced by other transcriptional regulatory factors that bind to sites contiguous to the E2F-binding sites (e.g., Sp1 sites in the TK and DHFR promoters (Lin et al., 1996; Karlseder et al., 1996; Rotheneder et al., 1999) , cell-cycle gene homology region (CHR)/downstream repressive site (DRS) in the B-myb promoter , and the YY1-binding site in the cdc6 promoter (Schlisio et al., 2002) ). These factors have been deduced to stabilize the interactions of specific free E2F members or E2F-pocket protein complexes with DNA and act synergistically in the activation or repression of transcription.
To elucidate the role of E2F-binding sites in regulating the expression of E2F-responsive genes, in this study, we analysed the transcriptional regulation of the E2F1 promoter, which contains two overlapping E2F-binding sites and provide a model for the specific roles of the E2F-binding sites in transcriptional regulation of the E2F1 promoter.
Results

Establishment of REF52 cell lines with stably integrated E2F1 promoter reporter plasmids
To investigate the role of E2F-binding sites in controlling the expression of E2F-responsive genes, we analysed the transcriptional activity of the E2F1 promoter, which includes two overlapping E2F-binding sites and is activated at the G1/S transition in an E2F-dependent manner, as a model of E2F-responsive genes. Mutations were introduced into both or either of these sites in reporter plasmids carrying the luciferase gene under the human E2F1 promoter containing the region 242 bp upstream of the transcription initiation site that retains elements required for cell-cycle-regulated E2F1 transcription (Figure 1a,b) (Johnson et al. 1994) . Henceforth, we refer to the distal side (position À31 to À20) of E2F-binding sites as 'E2F site A' and to the proximal side (position À14 to À3) as 'E2F site B'. To examine functional correlation between the role of the E2F-binding sites in controlling the E2F1 promoter activity and the interaction of E2F members with these sites, we first generated REF52 cell lines that integrate these reporter plasmids into chromatin. REF52 cells were transfected with these reporters along with a neomycin resistance expression vector and pCMV b-gal as an internal control, and selected with Geneticin. To minimize particular positional effects on integrated plasmids in chromatin, we combined a large number of Geneticin-resistant colonies and examined them for the presence and copy number of these integrated plasmids by Southern blot analyses (Figure 1c ). Luciferase and b-galactosidase DNA fragments were hybridized to genomic DNA isolated from cell lines transfected with plasmids, but not to genomic DNA isolated from the untransfected REF52 cell line. The quantitation of integrated plasmids normalized by the intensity of endogenous GAPDH (data not shown) indicated that these cells harbored on average 16.770.8 copies of the reporter plasmids (Figure 1c , top) and 3.170.3 copies of pCMV b-gal (Figure 1c, bottom) . Furthermore, PCR analysis using pairs of primers designed to detect the exogenous E2F1 promoter (Figure 1e ) indicated that the transfected E2F1 reporter is integrated into chromatin, along with cotransfected expression vectors driven by the CMV promoter (Figure 1d ).
Transcriptional activity of the wild-type and various mutant E2F1 promoters during the cell cycle
To examine the relative contribution of the E2F-binding sites to cell-cycle-dependent E2F1 transcription, the activity of the integrated E2F1 reporters was assayed during the cell cycle. First, we investigated the cell-cycle profile of these stably transfected cell lines and confirmed that the REF52 cells that had integrated E2F1-Luc WT were efficiently induced into quiescence by serum starvation and synchronously re-entered the cell cycle after serum restimulation (Figure 2a ). Consistent with previous studies (Johnson et al., 1994; Smith et al., 1996; Lindeman et al., 1997; Leone et al., 1998) , Western blotting analysis of REF52 cells with stably integrated E2F1-Luc WT showed that E2F4 and p130, components of the G0 repressor complex, were localized to the nucleus in quiescent cells. In late G1 (16 h), p130 was hyperphosphorylated, the majority of E2F4 was localized to the cytoplasm and the expression of E2F1 and E2F3 was induced (Figure 2b ). These results indicated that these cell lines retained orderly protein expression and cell-cycle progression similar to those of the parental REF52 cell line. For the cell-cycledependent transcription assays, REF52 cells that had integrated reporter plasmids were serum starved and harvested every 4 h after serum restimulation (Figure 2c) . Consistent with previous studies, the activity of wildtype E2F1 promoter was low in G0 (0 h) and increased approximately sevenfold from late G1 to S phase (20 h). The activity of the promoter mutated into both E2F sites A and B was fivefold greater than that of the wildtype promoter in G0, and only slightly elevated throughout the cell cycle (Smith et al., 1996) . To define their roles more precisely, we investigated the activity of the E2F1 promoter mutated into each of them. As shown in Figure 2c , the mutation in E2F site A abolished transcriptional repression of the E2F1 promoter in G0, whereas the mutation in site B had no significant effect on transcriptional repression, but dramatically impaired G1/S transcriptional upregulation. We therefore concluded that these two E2F-binding sites play distinct roles in controlling cell-cycle-dependent E2F1 transcription: the E2F site A represses transcriptional activity of the E2F1 promoter in G0, whereas the E2F site B confers upregulation on transcription at the G1/S boundary.
Analysis of E2F binding to the E2F1 promoter in vitro
It is conceivable that the distinct roles of these two sites in controlling E2F1 transcription are attributable to the different binding specificities of individual E2F members to particular sites in each stage of the cell cycle. We therefore carried out electrophoretic mobility shift assays (EMSAs) by incubating radio-labeled oligonucleotides containing E2F site A (Mut E2F site B) or B (Mut E2F site A) with nuclear extracts from serumstarved REF52 cells (Figure 3a) . Controversially, the results of the assays indicated that E2F/p130 G0 complexes designated by antibody supershift assays with anti-p130 antibody and competition assays using excess amounts of unlabeled oligonucleotides can bind to the E2F site B, but binding to the E2F site A was hardly detected. To make these binding clear, probes were incubated with whole-cell extract from U2OS cells overexpressing E2F4 product (Figure 3b ), which is the predominant E2F in E2F/p130 complexes (Vairo et al., 1995; Ikeda et al., 1996) . Similar to the E2F/p130 complexes in Figure 3a , E2F4 showed overwhelming binding preference for the E2F site B. Next, we performed EMSAs to investigate the binding preference of the E2F1 product, which plays a positive role in the transcriptional control of E2F-responsive genes. The same as E2F4, all forms of E2F1 derived from the transfection of an E2F1 expression vector, that is, free E2F1 and the E2F1/endogenous Rb family complexes confirmed by antibody supershift assays as shown in Figure 3c left, also bound much more to the E2F site B (Figure 3c , right). Taken together, these findings indicated that E2F1 as well as E2F4 preferentially bind to the E2F site B in vitro.
Different promoter occupancy of the integrated mutant E2F1 promoters
The conflicting results shown in Figure 3a and b prompted us to investigate E2F binding under physio- In recent studies, chromatin immunoprecipitation assays (ChIPs) have been used to reveal in vivo promoter occupancy in many mammalian genes, and thus far this approach has provided faithful understanding of the E2F binding to promoters in vivo (Wells et al., 2000; Takahashi et al., 2000) . We therefore performed ChIPs with REF52 cell lines that had integrated E2F1 reporter plasmids using the pairs of primers specific to the exogenous plasmids. Consistent with previous studies demonstrating endogenous E2F1 promoter occupancy in T98G cells (Takahashi et al., 2000) , we detected robust binding of E2F4 and p130 to the integrated wild-type E2F1 promoter in G0 and of E2F1 and E2F3 in late G1 (Figure 4a , top). The specificity of our experiments was confirmed, since we did not detect any binding to the cointegrated CMV promoter, which does not show the response to E2Fs (Figure 4a , bottom). ChIPs Relative transcriptional activity of the wild-type and mutant E2F1 promoters. REF52 cell lines that had stably integrated the indicated E2F1-Luc reporters were serum starved and restimulated with serum. Cells were harvested at the times indicated and assayed for luciferase activity normalized to b-galactosidase activity. Data are shown as fold activation. The mean value of wild-type E2F1 promoter activity at 0 h was set equal to 1. Bars show the standard errors of three independent assays
Distinct roles of E2F-binding sites in the E2F1 promoter K Araki et al with cells that had integrated various mutant reporters revealed that E2F4 and p130 exclusively bound to the E2F site A (Mut E2F site B) in G0, whereas E2F1 and E2F3 intimately bound to the E2F site B (Mut E2F site A), and slightly to the E2F site A in late G1 (Figure 4b,c) . From these results, we concluded that transcriptional repression of the E2F site A in G0 is mediated by the recruitment of E2F4/ p130 repressor complex to the site A, and transcriptional upregulation of the E2F site B in late G1 is conferred by the interaction of E2F1 and E2F3 activators with the site B. Mutations in both E2F sites A and B precluded E2F binding to the E2F1 promoter in G0 and late G1, indicating the E2F-binding sites-specific recruitment of these proteins to the E2F1 promoter (Figure 4d ).
CHR contributes to transcriptional repression of E2F1
The question then arose as to how the E2F4/p130 complex recognizes the E2F site A specifically in G0, in spite of the great binding preference of the E2F/p130 complex to the E2F site B in vitro. One plausible answer currently proposed is that the binding specificity of E2F members is dependent on other factors binding to sites located contiguous to E2F-binding sites. We therefore focused on the CHR/DRS in the B-myb promoter, which acts as a corepressor element by stabilizing the interaction of E2F/p130 repressor complex with the E2F-binding site . The CHR-like sequence is located downstream of the E2F site A and the relative spacing between the E2F-binding site and this region is identical to that in the B-myb promoter (Figure 5a ) (Zwicker and Muller, 1997) . To investigate the transcriptional role of the putative CHR in transcriptional regulation of the E2F1 promoter, transient reporter assays were performed using reporters that were also mutated into the putative CHR as shown in Figure 1a ( Figure 5b ). In agreement with previous observations with the B-myb promoter, mutation in the putative CHR (Mut CHR) led to a fivefold elevation of the E2F1 promoter activity in G0, and it is noteworthy that the presence of the mutation in the E2F site A, in addition to the mutation in the putative CHR (Mut E2F site A and CHR), had no additional effect on the promoter activity in G0, suggesting that mutation in the putative CHR abrogates the E2F site A-mediated transcriptional repression. We therefore carried out ChIPs to elucidate the correlation between the CHR and E2F site A in transcriptional repression of E2F1 ( Figure 4e ). As shown in Figure 4c , E2F4/p130 strongly Figure 3 Analysis of E2F binding to the E2F1 promoter in vitro. Gel mobility shift assays were performed with 2 mg of nuclear cell extracts from serum-starved REF52 cells (a) or whole-cell extracts from U2OS cells transfected with either pCMV E2F4 and pCMV-HA-DP1 (b) or pCMV E2F1 and pCMV-HA-DP1 (c) (0.5 mg each). Extracts were incubated with probes in the absence (À) or presence of the antibodies indicated and a 100-fold excess of unlabeled wild-type or mutant type (Mut E2F sites A and B) oligonucleotides. The probes used are indicated at the bottom of lanes (a and c left) or represented as þ (b and c right). Whole-cell extracts from U2OS cells transfected with 1.0 mg of a control CMV vector were used in the asterisk lane (C left)
-----------------------------------------------------------
Distinct roles of E2F-binding sites in the E2F1 promoter K Araki et al bound to the E2F site A (Mut E2F site B), but these interactions were significantly impaired by mutation in the CHR (Mut E2F site B and CHR). Taken together, these findings demonstrate that the CHR is essential to the recruitment of E2F/p130 repressor complexes to the E2F site A and acts as a corepressor element for transcriptional repression of E2F1.
Discussion
In this study we analysed the transcriptional activity of the E2F1 promoter and found that two E2F-binding sites play distinct roles in controlling E2F1 transcription (Figure 2c ). Similar to the E2F1 promoter, a dual role of E2F members in positive and negative control of transcription has previously been documented in several promoters containing two E2F-binding sites (e.g., Htf9-a/RanBP1 (Di Fiore et al., 1999) , cdc6 (Schlisio et al., 2002) ), yet the in vivo occupancy of their particular E2F-binding sites was not demonstrated. We carried out ChIPs with cells containing exogenously integrated reporter genes, and this approach provided powerful information on in vivo protein-DNA interaction without improper protein expression and cell-cycle progression ( Figure 4 ). Our findings point to different in vivo occupancies of the particular E2F-binding sites in G0 and late G1; the E2F4/p130 repressor complex exclusively binds to the E2F site A and is responsible for the transcriptional repression in G0, whereas E2F1 and E2F3 activators preferentially bind to the E2F site B and contribute to the upregulation on transcription at the G1/S transition ( Figure 6 ). It has been previously shown that induction of ectopic E2F1 overproduction is sufficient to drive quiescent cells into S and the deregulated expression of E2F1 in normal cells results in apoptosis (Dyson, 1998; Harbour and Dean, 2000) . These observations suggest that E2F1 is a critical cellcycle regulator in the timing of the G1/S transition and the appropriate expression of E2F1 is important for cell survival. Taken together, we propose that the combination of positive and negative control through the two E2F-binding sites enables to confer the tight regulation of E2F1 transcription. We have shown that E2F1 and E2F3 preferentially bind to the E2F site B in late G1 (Figure 4b,c) . This may reflect the results of the in vitro binding assay, that is, that the binding affinity of E2F1 and E2F3 is dependent on the DNA sequences of the E2F-binding sites. Previous reports have described the physical interaction between Sp1 and E2F1-3 and demonstrated their cooperative DNA binding and transcriptional regulation of the TK promoter (Karlseder et al., 1996; Rotheneder et al., 1999) . Since the E2F1 promoter contains several sites for other transcriptional factors, such as Sp1 sites, an alternative possibility is that the DNA binding of E2F1 and E2F3 is influenced by other adjacent factors.
Our results provide evidence that the CHR element contributes to stabilizing the interaction of the E2F4/ p130 repressor complex with the E2F site A and is essential for the transcriptional repression of E2F1 in G0. Nevertheless, we were unable to identify the factor binding to the CHR and to determine the effect of the mutation in the CHR on E2F-DNA interaction by in vitro binding assay (data not shown). The CHR was found in cyclin A, cdc2, and cdc25C promoters, which include a 'cell-cycle-dependent element' (CDE) and are upregulated at the S/G2 transition, suggesting that CDE-CHR elements contribute to S/G2 phase specific gene expressio (Zwicker et al., 1995) . The cdc6 and cdc25A promoters, which contain two E2F-binding sites, also include the CHR, and their gene expression is induced at the G1/S transition (Ohtani et al., 1998; Hateboer et al., 1998; Vigo et al., 1999) . Although the role of the CHR in E2F-dependent transcriptional regulation of the cdc6 and cdc25A promoters has not yet been elucidated, it is noteworthy that transcriptional repression of these promoters in G0 is mediated by one of two E2F-binding sites and that the relative spacing between the repressive E2F-binding site and the CHR is identical to the spacing in the E2F1 and B-myb promoters (Hateboer et al., 1998; Vigo et al., 1999; Iavarone and Massague, 1999; Wu et al., 2000; Schlisio et al., 2002) . Based on these observations and our study, we propose that the diverse transcriptional regulation of E2F-responsive genes would be caused by interaction of specific E2F and Rb family members with other transcriptional regulatory factors. This is strongly supported by undetectable in vivo binding of E2F4 to the E2F site B, in spite of its high binding affinity to this site in vitro.
We observed functional cooperation between the E2F site A and the CHR in the E2F4/p130-mediated transcriptional repression in G0, and yet transcriptional derepression caused by the mutation in the CHR was found throughout the cell cycle ( Figure 5b ). As shown in Figure 2b , the bulk of p130 is hyperphosphorylated and E2F4 is localized in the cytoplasm in late G1, proposing the possibility that the CHR element acts as a transcriptional repressor in addition to in an E2F4/ p130-dependent manner.
Transcriptional activity of the E2F1 promoter in late G1 is increased approximately twofold by the mutation in the E2F site A (Figure 2c) , suggesting that the E2F site A contributes to transcriptional repression in late G1 as well as G0. Previous studies have demonstrated that E2F/p130 repressor complexes are primarily found in G0, while E2F/pRb complexes, composed of pRb and E2F1-3, are most evident in late G1 (Ikeda et al., 1996; Dyson, 1998) . As shown in Figure 4c and e, we detected definite binding of E2F1 and E2F3 to the E2F site A in late G1. Thus, to investigate whether the E2F site A-mediated transcriptional repression in late G1 is attributable to the E2F/pRb pathway, we carried out ChIPs with anti-pRb antibody (sc-49, Santa Cruz Biotechnology). Although we could not rule out the possibility that this antibody is incapable of being used in ChIPs, no association between pRb and the E2F1 promoter was detected in late G1 (data not shown), which is supported by previous experiments analysing in vivo binding to endogenous E2F1 promoter (Takahashi et al., 2000) . While it is possible that the elevation of the E2F1 promoter activity caused by the mutation in E2F Figure 6 Model for in vivo occupancy of the E2F1 promoter during the cell cycle. In quiescent cells, the interaction of E2F4/ p130 with the E2F site A, which appears to be stabilized by a CHR binding factor, mediates transcriptional repression. In contrast, E2F1 and 3 preferentially bind to the E2F site B and lead to transcriptional activation in late G1
Distinct roles of E2F-binding sites in the E2F1 promoter K Araki et al site A is attributable to the exclusion of a functional repressor complex other than the pocket protein complexes, an alternative explanation is that the promoter activity is affected by the acetylated state of nucleosomal histones that is closely related to the local structure of chromatin DNA. A recent study has demonstrated that p130 and p107 are responsible for the recruitment of a chromatin-modifying factor, histone deacetylase (HDAC1), to the E2F1 promoter, and loss of HDAC1 recruitment is well correlated with elevation of histone acetylation and activation of the promoter (Rayman et al., 2002) . Thus, evidence presented here supports the notion that the exclusion of p130 by the mutation in the E2F site A prevents the recruitment of HDAC1 to the E2F1 promoter, causing the subsequent elevation of histone acetylation which appears to facilitate the accessibility of transcriptional regulatory proteins and/or components of the basal transcriptional machinery to the promoter in G0. In this regard, an enhancement of the site A mutated promoter activity in late G1 might be due to acceleration of the formation of a functional transcriptional complex on the promoter upon serum stimulation. It will be of interest to make clear the roles of E2F site A and CHR element in control of the transcriptional activity of the E2F1 promoter in late G1.
Materials and methods
Plasmids
The human E2F1 promoter reporter plasmid (E2F1-Luc (-242)) WT was provided by Dr K Ohtani (Johnson et al., 1994) . Mutations were introduced into both or either of two putative E2F recognition sites and/or the CHR on the E2F1 promoter region of the E2F1-Luc (-242) WT by site-directed mutagenesis using a U.S.E. Mutagenesis Kit (Pharmacia Biotech). Wild-type and mutants of the E2F1 reporter are schematically illustrated in Figure 1a .
Cell culture REF52 and U2OS were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum (FCS). To induce cells into quiescence, REF52 cells were washed three times with PBS and then placed in DMEM containing 0.1% FCS for 48-72 h. The cells were stimulated by replacement with DMEM containing 20% FCS to allow cell-cycle re-entry.
Transfection and luciferase assay REF52 cells plated in 12-well plates (4 Â 10 4 cells/well) were transfected with E2F1-Luc reporter plasmids along with bgalactosidase expression plasmid pCMV b-gal, as an internal control, by using FuGENE6 transfection reagent (Roche Diagnostics). Luciferase activity was normalized to b-galactosidase activity. All assays were performed at least three times in duplicate and independently.
Generation of stably transfected cell lines and southern blotting analyses
To generate REF52 cell lines stably transfected with E2F1-Luc reporter genes, cells were transfected with either one of the E2F1-Luc reporter plasmids along with pCMV b-gal, as an internal control, and pcDNA3-neo at a ratio of 10 : 3 : 1 and selected with 800 mg/ml of G418 for 2 weeks. The resulting G418-resistant colonies were pooled and expanded under selection.
Southern blotting analyses were performed by using standard procedures. EcoRV-XbaI digested genomic DNA (5 mg) from the stable transfectants and the indicated amount of E2F1-Luc plasmid DNA were separated and transferred to a positively charged nylon membrane (Roche Diagnostics). For b-galactosidase gene, DraI-EcoRV digested genomic DNA (6 mg) and the indicated amount of pCMV b-gal were separated and transferred. The blots were probed with the EcoRV-XbaI fragment of the luciferase gene and DraI-EcoRV fragment of the b-galactosidase gene, respectively, and the bands were quantitated on a BIO imaging analyzer 2500 (Fujifilm). For sample loading controls, the blots were reprobed with a GAPDH cDNA. The densitometric values of the luciferase and b-galactosidase genes in each cell line were normalized to those of endogenous GAPDH.
Laser scanning cytometry
REF52 cells stably transfected with E2F1-Luc WT were plated on a coverslip and serum starved. Cells were harvested at the indicated times after serum stimulation. Cells were fixed with 75% ethanol and stained with buffer containing propidium iodide (50 mg/ml) and RNaseA (200 mg/ml). The cell-cycle profile was analysed with a Laser Scanning Cytometer (LSC101 Olympus).
Western blotting analysis
Western blotting analysis was performed by using standard procedures. Equal amounts (50 mg) of nuclear and cytoplasmic extracts prepared from REF52 cells that had been stably transfected with E2F1-Luc WT were separated and transferred to a polyvinylidene difluoride membrane (Pall Gelman Laboratory). The blot was probed with primary antibodies directed against E2F1 (sc-193), E2F3 (sc-878), E2F4 (sc-1082), p130 (sc-317), or actin (sc-7210) (Santa Cruz Biotechnology).
EMSAs
EMSAs were performed as described previously (Ikeda et al., 1996) . Equal amounts of the extracts (2 mg) were incubated with 0.4 ng of radio-labeled probes in the absence or presence of unlabeled oligonucleotide competitors (40 ng) and 100 ng of antibodies (E2F1, sc-193; E2F4, sc-1082; Rb, sc-50; p107, sc-318; p130, sc-317) . The following double-stranded oligonucleotides were used as probes and cold competitors:
E2F1 WT (5 0 -CGTGGCTCTTTCGCGGCAAAAAGGAT TTGGCGCGTAAAAGT-3 0 ); E2F1 Mut E2F site A (5 0 -CGT GGCTCTTTCGATGCAAAAAGGATTTGGCGCGTAAAA GT-3 0 ); E2F1 Mut E2F site B (5 0 -CGTGGCTCTTTCGC GGCAAAAAGGATTTGGATCGTAAAAGT-3 0 ); E2F1 Mut E2F site A and B (5 0 -CGTGGCTCTTTCGATGCAAAAAG-GATTTGGATCGTAAAAGT-3 0 ).
CHIPs
ChIPs were performed as described previously (Takahashi et al., 2000) . Each cell line of REF52 cells cultured on f150 mm dishes (2 Â 10 7 cells) was crosslinked with formaldehyde solution and lysed. Nuclei were sonicated and separated by CsCl step-gradient centrifugation. Crosslinked chromatins were collected and precleared with ProteinA/Sepharose 4B beads (Amersham Biosciences) previously blocked with sonicated salmon sperm DNA (100 mg/ml) and BSA (100 mg/ ml). Precleared chromatin was incubated with 2 mg of each antibody (E2F1, sc-193; E2F3, sc-878; E2F4, sc-1082; p130, sc-317) at 41C overnight. Normal rabbit IgG was used for the mock immunoprecipitation. Immunocomplexes were recovered with 30 ml of ProteinA/Sepharose 4B beads and washed eight times with RIPA buffer (0.5 m LiCl, 50 mm HEPES (pH 7.5), 1 mm EDTA, 1% NP40, 0.7% sodium deoxycholate) containing proteinase inhibitors (complete mini, Roche Diagnostics) and twice with TE buffer. To reverse the crosslinks, the pellets were incubated in 100 ml of TE buffer containing 0.5% SDS, 10 mg RNaseA, and 10 mg Proteinase K at 551C for 3 h and then at 651C for 16 h. The resulting DNA was purified by phenol-chloroform and ethanol precipitation. Pellets were dissolved in 50 ml H 2 O and subjected to semiquantitative PCR. For input control, 1/200 volume of chromatin was amplified. Each experiment was repeated two to three times, and representative data are shown.
PCR reaction
PCR amplifications were carried out in 10 ml with 0.25 U of Taq DNA polymerase (Sigma), 0.5 mCi of [a-
32 P]dCTP, 10 pmol of each primer set, and 4% of DMSO. Each reaction was performed using the following pairs of primers: E2F1 promoter-luciferase gene (5 0 -AGGAACCGCCGCCGTTG TTCCCGT-3 0 and 5 0 -GGATAGAATGGCGCCGGGCCTTT C-3 0 ); CMV promoter (5 0 -TTCCCATAGTAACGCCAA-TAGGGA-3 0 and 5 0 -GCATCACCATGGTAATAGCGAT-GA-3 0 ); GAPDH (5 0 -ACCACAGTCCATGCCATCAC-3 0 and 5 0 -TCCACCACCCTGTTGCTGTA-3 0 ). PCR products were separated by electrophoresis through an 8% polyacrylamide gel and visualized by using a BIO imaging analyzer 2500 (Fujifilm).
